Rakovina Therapeutics Inc. and NanoPalm Ltd. have signed a Letter of Intent to co-develop small-molecule oncology therapeutics using AI-powered drug discovery and pLNP delivery systems. The collaboration will focus on loading Rakovina’s PARP-HDAC inhibitor, kt3283, into Nano Palm’s pLNP technology, which has shown promising results in preclinical studies for Ewing sarcoma, breast, and ovarian cancer. This joint venture aims to advance kt-3283 through late preclinical development and early clinical studies while exploring global licensing opportunities. The JV will be domiciled in Saudi Arabia, aligning with the Kingdom’s National Biotechnology Strategy for innovative biotech development.

Read more at GlobeNewswire: Rakovina Therapeutics and NanoPalm Ltd. Sign Letter of